Download PPT - Altogen Biosystems

Leading Developer and Manufacturer of In Vivo and DNA Transfection
Kits, Transfection Reagents and Electroporation Delivery Products
Products > LNCAP
Transfection Reagent (Prostate Carcinoma)
Altogen Biosystems offers the LNCAP Transfection Reagent
among a host of 100+ cell line specific In Vitro Transfection
Kits.
The LNCAP Transfection Reagent is a nanoparticle-based
liposome formulation, and it has been developed to provide
high transfection efficiency with the LNCAP cell line.
This cell line is a good host for studying prostate and
hormone functions. When cultured in vitro, LNCAP cells are
a monolayer and adhere to the surface of the culture flask.
Other applications include drug discovery, gene expression
studies, molecular and cell biology research applications.
Purchase LNCAP Transfection Kit at www.Altogen.com
Altogen Biosystems  848 Rainbow Blvd #823  Las Vegas  NV  89107  USA
Telephone  702 349 6103  Fax  702 989-0841  email  [email protected]
Leading Developer and Manufacturer of In Vivo and DNA Transfection
Kits, Transfection Reagents and Electroporation Delivery Products
Products > LNCAP
Transfection Reagent (Prostate Carcinoma)
LNCAP Cell Line Description and Applications
High Density LNCAP cells
Atcc.org
The LNCaP cell line originates from a metastatic site of
human prostate adenocarcinoma cells. The cell line
was derived in 1977 from the supraclavicular lymph
node of a 50-year old Caucasian male. The LNCaP cell
line can grow as both a single cell or in aggregate form
and displays adherent epithelial morphology. The cell
line is also is also receptive to hormones and has a high
affinity for androgen receptors and nuclear fractions of
cells. Furthermore, the cytosol contains estrogen
receptors. The LNCaP also produces Prostate Specific
Antigen. Research with hormonal manipulations
indicate that tumor development correlates with serum
androgen levels. This cell line is hypotetraploid and the
modal chromosome number is 84.
Altogen Biosystems  848 Rainbow Blvd #823  Las Vegas  NV  89107  USA
Telephone  702 349 6103  Fax  702 989-0841  email  [email protected]
Leading Developer and Manufacturer of In Vivo and DNA Transfection
Kits, Transfection Reagents and Electroporation Delivery Products
Products > LNCAP
Transfection Reagent (Prostate Carcinoma)
LNCAP Transfection Protocol
1. Plate 10,000 - 15,000 LNCAP cells per well in 0.5 ml of complete growth medium 12–24 hours prior to
transfection
2. Wash with 1xPBS and add 0.5 ml of fresh growth medium
3. Prepare transfection complexes by mixing 40 µl of serum-free medium, 5.5 µl of transfection reagent,
and
• 750 ng DNA (or mRNA), or
• 30 nM - 50 nM of siRNA (or microRNA)
*Referred to a final volume including growth medium
4. Incubate transfection complexes at RT for 15 - 30 minutes
5. Optional: Add 2 µl of Complex Condenser. This reagent reduces the size of transfection complex,
therefore increasing transfection efficiency; however it may increase cell toxicity
6. Add prepared transfection complexes to 0.5 ml of complete growth medium with LNCAP cells (from
step 2)
7. Incubate cells at 37ºC in a humidified CO2 incubator
8. Assay for phenotype or target gene expression 48 - 72 hours after transfection
Optional: Transfection efficiency can be increased by addition of Transfection Enhancer reagent. Add 2 µl of
Transfection Enhancer reagent 12-24 hours after transfection
If the viability of LNCAP cells being transfected is affected at 16 - 24 hours post-transfection, the level of
cytotoxicity can be decreased by changing the growth medium and eliminating redundant exposure of cells to
transfectant
Altogen Biosystems  848 Rainbow Blvd #823  Las Vegas  NV  89107  USA
Telephone  702 349 6103  Fax  702 989-0841  email  [email protected]
Leading Developer and Manufacturer of In Vivo and DNA Transfection
Kits, Transfection Reagents and Electroporation Delivery Products
Products > LNCAP
Transfection Reagent (Prostate Carcinoma)
General Lipoplex-mediated Transfection Mechanism of Action
Altogen Biosystems  848 Rainbow Blvd #823  Las Vegas  NV  89107  USA
Telephone  702 349 6103  Fax  702 989-0841  email  [email protected]
Leading Developer and Manufacturer of In Vivo and DNA Transfection
Kits, Transfection Reagents and Electroporation Delivery Products
Products > LNCAP
Transfection Reagent (Prostate Carcinoma)
LNCAP Transfection Kit Product Details
•A nanoparticle-based liposome formulation
•Transfection protocols provided for transfection of proteins, DNA, mRNA, siRNA, shRNA and
microRNA
•Transfection Enhancer reagent provided with the kit
•Produce higher level of recombinant protein expression with minimal disruption of normal cell function
•Generate physiologically relevant data you can trust
•Effective for plasmid DNA/siRNA co-transfection
•Easy-to-use transfection protocol with reproducible results
•Low cytotoxicity
Developed and manufactured by Altogen Biosystems (www.Altogen.com)
Altogen Biosystems  848 Rainbow Blvd #823  Las Vegas  NV  89107  USA
Telephone  702 349 6103  Fax  702 989-0841  email  [email protected]
Leading Developer and Manufacturer of In Vivo and DNA Transfection
Kits, Transfection Reagents and Electroporation Delivery Products
Products > LNCAP
Transfection Reagent (Prostate Carcinoma)
Data
Figure 1. SiRNAs targeting Lamin A/C mRNA or non-silencing control siRNA were transfected into LNCaP cells
following the recommended protocol. At 48 hours post-transfection the cells were analyzed by qRT-PCR for
gene expression levels. 18S rRNA levels were used to normalize the Lamin A/C data. Values are normalized to
untreated sample. Data are means ± SD (n=3).
Leading Developer and Manufacturer of In Vivo and DNA Transfection
Kits, Transfection Reagents and Electroporation Delivery Products
Products > LNCAP
Transfection Reagent (Prostate Carcinoma)
Data
Figure 2. Protein expression of Lamin A in LNCAP cells. DNA plasmid expressing Lamin A or siRNA targeting
Lamin A were transfected into LNCAP cells following Altogen Biosystems transfection protocol. At 72 hours
post-transfection the cells were analyzed by Western Blot for protein expression levels (normalized by total
protein, 10 µg of total protein loaded per each well). Untreated cells used as a negative control.
Leading Developer and Manufacturer of In Vivo and DNA Transfection
Kits, Transfection Reagents and Electroporation Delivery Products
Products > LNCAP
Transfection Reagent (Prostate Carcinoma)
LNCAP Transfection Kit Benefits
• Pre-optimized transfection protocol for LNCAP cell line
• Compatible with DNA, small RNA (siRNA, shRNA, miRNA), mRNA, and small protein complexing
• Free of serum and protein of animal origin
• Compatible with standard and reverse transfection methods (both protocols provided in the kit manual)
• Easy to use LNCAP transfection protocol ensures great performance with expedited experimental timeline
• Equally efficient for single or multiple transfections
• Can be used for transient transfection and development of stable LNCAP cell lines
• Bio-degradable after endocytosis
• Used for preclinical research worldwide
Altogen Biosystems  848 Rainbow Blvd #823  Las Vegas  NV  89107  USA
Telephone  702 349 6103  Fax  702 989-0841  email  [email protected]